empty
 
 

2024.06.2807:13:00UTC+00AbbVie: CHMP Adopts Positive Opinion Recommending Conditional Marketing Authorization Of Epcoritamab

AbbVie (ABBV) has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has rendered a positive opinion, recommending the conditional marketing authorization of epcoritamab. This is the first T-cell engaging bispecific antibody to be administered subcutaneously and is intended for use as a monotherapy in adult patients with relapsed or refractory follicular lymphoma who have undergone two or more prior treatments. A decision from the European Commission on this indication is anticipated later this year.

Epcoritamab is being co-developed by AbbVie and Genmab. The companies will share commercial responsibilities in the U.S. and Japan, while AbbVie will oversee further global commercialization efforts.

For further health news, visit news.com.

  • Grand Choice
    Contest by
    InstaForex
    InstaForex always strives to help you
    fulfill your biggest dreams.
    JOIN CONTEST
  • Chancy Deposit
    Deposit your account with $3,000 and get $4000 more!
    In July we raffle $4000 within the Chancy Deposit campaign!
    Get a chance to win by depositing $3,000 to a trading account. Having fulfilled this condition, you become a campaign participant.
    JOIN CONTEST
  • Trade Wise, Win Device
    Top up your account with at least $500, sign up for the contest, and get a chance to win mobile devices.
    JOIN CONTEST
  • 30% Bonus
    Receive a 30% bonus every time you top up your account
    GET BONUS


Can't speak right now?
Ask your question in the chat.
Widget callback